AngioDynamics (NSDQ:ANGO) roped in another FDA win for its BioFlo device, the 2nd clearance for a product line the medical device company picked up through its $372 million Navylist buyout.

BioFlo is a line of catheter-related devices designed to cut the risk of blood clots. Last year’s acquisition brought the catheter technology under AngioDynamics’ wing.

Albany, N.Y.-based AngioDynamics brought the 1st BioFlo product, BioFlo PICC, to the market soon after the 2012 acquisition. The company expects a product launch of the new BioFlo port in the 3rd quarter of next year.

The BioFlo Port has a as special surface that reduces the risk of developing thrombus, or blood clotting. The device’s surface polymer, called Endexo, is designed to resist the blood platelet accumulation that leads to clotting.

"We’re pleased to build on the success of our BioFlo PICC by introducing the first port with a demonstrated reduction in thrombus accumulation," CEO Joseph DeVivo said in prepared remarks.

In a separate release, AngioDynamics said it kicked off a trial of its NanoKnife prostate cancer ablation device. AngioDynamics enrolled the 1st patient to be treated with NanoKnife, which breaks up tissue before a surgical removal of the prostate gland.

The 1st study evaluating NanoKnife will enroll 16 patients. AngioDynamics said ultimately a 2nd study will evaluate the treatment in 200 patients.